COVID-19: Sodium phenylbutyrate
Sodium phenylbutyrate has been funded since July 2016 for the treatment urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase subject to Special Authority criteria.
Page updated: 9 April 2020
Renewal of Special Authority
We have removed the requirement for a metabolic physician to apply for renewals of the Special Authority to fund sodium phenylbutyrate .
Any relevant physician can apply to renew the Special Authority.
Section H of the Pharmaceutical Schedule will also be amended to reflect this change.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email email@example.com
Last updated: 15 April 2020